The newly named Krantz Family Center for Cancer Research will empower Mass General Cancer Center researchers to tackle the major unsolved challenges in oncology.
- In patients with Alzheimer’s disease, amyloid-beta protein fragments accumulate in the tissue and blood vessels of the brain
- Very slow spontaneous vessel pulsations drive the clearance of substances from the brain
- Targeting and improving this process may help to prevent or treat amyloid-beta accumulation
Susanne van Veluw, PhD
If we direct therapeutic strategies towards promoting healthy vasculature and therefore improve clearance of amyloid-beta from the brain, we may be able to prevent or delay the onset of Alzheimer’s disease in the future.”
Department of Neurology, Massachusetts General Hospital
BOSTON – In patients with Alzheimer’s disease, amyloid-beta protein fragments accumulate in the tissue and blood vessels of the brain, likely due to a faulty clearance mechanism. In experiments conducted in mice, investigators at Massachusetts General Hospital (MGH) have found that very slow spontaneous vessel pulsations – also known as ‘vasomotion’ – drive the clearance of substances from the brain, indicating that targeting and improving this process may help to prevent or treat amyloid-beta accumulation.
In their study published in Neuron, the researchers injected a fluorescently labeled carbohydrate called dextran into the brains of awake mice, and they conducted imaging tests to follow its clearance. Their experiments revealed that vasomotion was critical for clearing dextran from the brain and stimulating an increase of the amplitude of these vessel pulsations could increase clearance. Also, in mice with cerebral amyloid angiopathy, a condition that causes amyloid-beta to build up in the walls of the brain’s blood vessels, vessel pulsations were hindered and clearance rates were reduced.
“We were able to show for the first time that large dilations and contractions of vessels that happen spontaneously at an ultra-low frequency are a major driving force to clear waste products from the brain,” said lead author Susanne van Veluw, PhD, an investigator in the department of Neurology at MGH. “Our findings highlight the importance of the vasculature in the pathophysiology of Alzheimer’s disease. If we direct therapeutic strategies towards promoting healthy vasculature and therefore improve clearance of amyloid-beta from the brain, we may be able to prevent or delay the onset of Alzheimer’s disease in the future.”
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $1 billion and comprises more than 8,500 researchers working across more than 30 institutes, centers and departments. In August 2019 the MGH was once again named #2 in the nation by U.S. News & World Report in its list of "America’s Best Hospitals."
Related News and Articles
- Sep | 26 | 2023
A more detailed understanding of the connections between brain networks could improve treatments for neurological and psychiatric disorders.
- Sep | 26 | 2023
The life and work of Warren M. Zapol, MD, might best be described as a series of sparks.
- Sep | 26 | 2023
Research Spotlight: Association of food insecurity on body mass index change in a pediatric weight management intervention
Short description of the study goes here. And be sure to update the link below to the new spotlight page you just created.
- Press Release
- Sep | 21 | 2023
Sean M. Healey & AMG Center for ALS and the University of California, Irvine Announce First Participant Enrolled in Expanded Access Protocol Program for Trehalose
The University of California, Irvine (UCI) successfully enrolled the first participant in its newly established Expanded Access Protocol (EAP) program.
- Sep | 20 | 2023
Research Spotlight: Population Health Impact, Cost-Effectiveness, and Affordability of Community-Based HIV Treatment and Monitoring in South Africa: A Health Economics Modelling Study
A modeling study projects that by 2060, community-based HIV treatment and monitoring averts 28% of HIV-related deaths and 28% of new infections.